Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | - | - |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.17 | 2.26 |
NAV | ₹10.45 | ₹170.33 |
Fund Started | 02 Jul 2025 | 13 Oct 2005 |
Fund Size | ₹955.61 Cr | ₹1420.55 Cr |
Exit Load | Exit load of 1%, if redeemed within 365 days | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | - | 6.59% |
3 Year | - | 18.78% |
5 Year | - | 21.35% |
1 Year
3 Year
5 Year
Equity | 96.95% | 96.69% |
Cash | 3.05% | 3.31% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
HDFC Bank Ltd. | 6.16% |
Reliance Industries Ltd. | 4.16% |
ICICI Bank Ltd. | 4.07% |
Infosys Ltd. | 3.09% |
AU Small Finance Bank Ltd. | 2.56% |
Bharat Electronics Ltd. | 2.48% |
Kaynes Technology India Ltd. | 2.36% |
Bharti Airtel Ltd. | 2.25% |
Glaxosmithkline Pharmaceuticals Ltd. | 2.09% |
Godfrey Phillips India Ltd. | 2.07% |
Name | Assets |
|---|---|
Infosys Ltd. | 8.79% |
Reliance Industries Ltd. | 6.82% |
ICICI Bank Ltd. | 6.53% |
HDFC Bank Ltd. | 5.93% |
NTPC Ltd. | 4.63% |
Larsen & Toubro Ltd. | 4.59% |
Bharti Airtel Ltd. | 3.99% |
Sun Pharmaceutical Industries Ltd. | 3.69% |
Tata Consultancy Services Ltd. | 3.01% |
Dr. Reddy's Laboratories Ltd. | 2.87% |
Name | Dwijendra Srivastava | Sri Sharma |
Start Date | 02 Jul 2025 | 30 Apr 2021 |
Name
Start Date
Description | The scheme seeks to provide long-term capital growth to its Unitholders by following a multi factor based investment strategy. | The scheme seeks to generate capital appreciation and income distribution to unit holders by investing predominantly in equity/equity related securities of the companies belonging to Exports & Services industry. |
Launch Date | 02 Jul 2025 | 13 Oct 2005 |
Description
Launch Date